Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visilizumab for Acute GVHD
NCT00032292Phase 2Completed
- Sponsor
- Facet Biotech Corporation
- Start
- Mar 2002
- Primary completion
- Aug 2006
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of visilizumab in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Facet Biotech Corporation. Started Mar 2002; status: completed.
02
Drugs
visilizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT00032292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00032292.